Study in patients with moderate to severe psoriasis with secukinumab

Update Il y a 4 ans
Reference: EUCTR2014-002212-16

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To demonstrate that secukinumab has superior efficacy compared to placebo on the pruritus intensity VAS (the worst itching within a recall period of 24 hours as part of the Patients Global Assessment of Chronic Pruritus, PGA-CP) measured at week 32 in patients with moderate to severe psoriasis.


Inclusion criteria

  • chronic moderate to severe plaque type psoriasis

Links